Industry news

News of the day

Industry news search

Recent news

To keep up to date with news from this category use our

Neuronetics selected by World Economic Forum as 2011 Technology Pioneer
Malvern, PA, [September 1, 2010] - Neuronetics, Inc., maker of the NeuroStar TMS (Transcranial Magnetic Stimulation) Therapy

QRxPharma to Sponsor Symposium at International Association for the Study of Pain Meetings
Sydney, Australia and Bedminster, New Jersey -August 31, 2010 -QRxPharma (ASX: QRX and OTCQX: QRXPY) announced today it will sponsor a symposium at the IASP (International Association for the Study of Pain) 13th...

Bayer
Berlin, Germany, August 31, 2010 - The Phase III EINSTEIN-DVT clinical trial of the oral anticoagulant rivaroxaban demonstrated non-inferiority compared to the standard of care for the prevention of recurrent venous...

PharmaNet Joins Medidata Solutions' CRO Partner Program
NEW YORK, N.Y. - August 31, 2010 - Medidata Solutions (NASDAQ: MDSO), a leading global provider of SaaS-based clinical development solutions, today announced that PharmaNet Development Group has joined Medidata's...

Randomized Controlled Trial Finds Masimo PVI Improves Fluid Management During Surgery
Irvine, California - August 31, 2010 - Masimo (NASDAQ: MASI) announced today that a new randomized controlled trial published in Anesthesia & Analgesia shows that clinicians using Masimo Pleth Variability Index (PVI

Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study
Stockholm, SE (August 31, 2010) -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigational, oral anticoagulant rivaroxaban successfully demonstrated...

Prometheus Launches the First Serogenetic Test to Predict Risk of Complications from Crohn's Disease
San Diego, August 31, 2010 - Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the commercial launch of its proprietary PROMETHEUS

PHT Corporation Completes Audit of Quality Management System by TUV Rheinland of North America and Discusses Quality in Clinical Trials
BOSTON, Mass - August 31, 2010 - PHT Corporation announced that its ISO certification received an upgrade to ISO9001:2008 following the successful completion of an audit of its Quality Management System by TUV...

Publication of Phase II trial results of NGR-hTNF in liver cancer by the British Journal of Cancer
Milan (Italy), August 31, 2010 - MolMed S.p.A. (Milan:MLM) announces that the positive results of a phase II trial of its investigational anticancer drug NGR-hTNF in liver cancer have been published by the British...

Pivotal Phase 3 Study Compares Tapentadol Extended Release Tablets to Placebo in Patients with Chronic Osteoarthritis Knee Pain
Raritan, NJ - (August 30, 2010) - Phase 3 safety and efficacy data comparing tapentadol extended release (ER) tablets, an investigational pain medication, to placebo in patients with moderate to severe chronic...

Intendis and KYTHERA Enter Licensing and Development Agreement on Adipolytic Agent for Aesthetic Dermatology Use
Berlin, August 30, 2010 -- Bayer HealthCare's dermatology business Intendis and KYTHERA Biopharmaceuticals, Inc. today announced an agreement to develop and commercialize ATX-101; an adipolytic agent designed to...

Forest Laboratories, Inc. and Gedeon Richter Plc Announce Results from a Phase II Study of Cariprazine for the Treatment of Bipolar Depression
NEW YORK & BUDAPEST, Hungary, Aug 30, 2010 -- Forest Laboratories, Inc. (NYSE: FRX) and Gedeon Richter Plc. today announced preliminary top-line results from an 8-week Phase II clinical trial of the novel,...

SciBase successfully achieves clinical study objectives
August 30, 2010--Swedish medtech company SciBase is in the final stage of development with its unique method for first line detection of malignant melanoma. A clinical study has recently been completed involving 1200...

European Medicines Agency starts review of Pandemrix
August 27, 2010 --The European Medicines Agency has launched a review of Pandemrix on the request of the European Commission to investigate whether there is a link between cases of narcolepsy and vaccination with...

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
CAMBRIDGE, Mass.--August 27, 2010--Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt,...

Idera Pharmaceuticals Achieves Clinical Milestone Under Its Collaboration with Merck KGaA for Cancer Treatment
CAMBRIDGE, Mass., Aug 27, 2010 -- Idera Pharmaceuticals, Inc. (Nasdaq: IDRA), today announced that it has achieved a milestone under its worldwide licensing and collaboration agreement with Merck KGaA, Darmstadt,...

Roche provides update on FDA application for T-DM1
Basel, 27 August 2010--Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval for the company's trastuzumab-DM1...

Ricerca Biosciences Successfully Completes cGMP Prep HPLC Purification
CONCORD, Ohio-August 27, 2010--Ricerca Biosciences, an integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the successful...

Alexza's Staccato(R) Nicotine Licensed to Cypress Bioscience
MOUNTAIN VIEW, Calif., Aug 26, 2010 -- Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) announced today that it has licensed its Staccato nicotine technology to Cypress Bioscience, Inc. (Nasdaq: CYPB). The Staccato...

Vanda Pharmaceuticals Initiates Phase III Clinical Study Aimed at Resetting the Body Clock
ROCKVILLE, Md., Aug 26, 2010 --Vanda Pharmaceuticals Inc. (Nasdaq: VNDA), today announced it has initiated a Phase III clinical trial to evaluate tasimelteon in patients with Non-24-Hour Sleep Wake Disorder...

Luminex Announces Commercial Launch of New Cystic Fibrosis Test
AUSTIN, Texas, Aug 26, 2010 - Luminex Corporation (Nasdaq: LMNX), the worldwide leader in multiplexed solutions, today announced the full commercial launch of its xTAG(R) Cystic Fibrosis 60 Kit v2, a new diagnostic...

Ricerca Biosciences Successfully Completes cGMP Prep LC Purification
CONCORD, Ohio--August 26, 2010--Ricerca Biosciences, a uniquely integrated preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, is pleased to announce the successful...

Genentech Provides Update on FDA Application for T-DM1
South San Francisco, Calif. -- August 25, 2010 -- Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for...

Advanced Life Sciences Sees Funding Opportunity for Restanza in New HHS Medical Countermeasure Report
CHICAGO, Aug 24, 2010 - Advanced Life Sciences Holdings, Inc. (OTC Bulletin Board: ADLS), a biopharmaceutical company engaged in the discovery, development and commercialization of novel drugs in the therapeutic...

Raptor Pharmaceutical Provides Financial and Clinical Program Updates
NOVATO, Calif., Aug. 24, 2010-- Raptor Pharmaceutical Corp. ("Raptor" or the "Company") (Nasdaq:RPTP), provides updates on timelines related to its clinical programs including the pivotal Phase 3 clinical trial of...

StemCells, Inc. Reports Breakthrough Using Human Neural Stem Cells to Restore Motor Function in Chronic Spinal Cord Injury
PALO ALTO, Calif., August 19, 2010 - StemCells, Inc. (NASDAQ: STEM), announced today the publication of new preclinical data demonstrating that the Company's proprietary human neural stem cells restore lost motor...

Pluristem's PLX Cells Found to be Effective in Treating Neuropathic and Inflammatory Pain
HAIFA, Israel-- August 09, 2010--Pluristem Therapeutics Inc. (NasdaqCM: PSTI) (DAX: PJT) today announced the results of two separate pre-clinical studies in animal models which demonstrated that its PLacental...

YM BioSciences announces conclusion of Phase I dose-escalation and expansion of ongoing CYT387 Phase I/II clinical study
MISSISSAUGA, ON, Aug 05, 2010--YM BioSciences Inc. (NYSE Amex:YMI, TSX:YM), announced the conclusion of dose-escalation in the Phase I portion of its Phase I/II clinical trial of CYT387 at Mayo Clinic in patients...

Clinical Phase I Results of GANYMED's iMAB362 Antibody Demonstrate Excellent Safety
Mainz, Germany, August 04, 2010 - A clinical first-in-human Phase I multi center study with GANYMED's monoclonal antibody iMAB362 demonstrated excellent safety up to a dosis of 1g/sqm in gastro-esophageal cancer...

Almac launch Biomarkers for biopharma
02-AUG-10--Almac today announced the launch of Biomarkers for biopharma; a range of solutions specifically designed to meet the needs of the biopharma industry.

Two-Thirds Respond to "Re-vaccination "
August 01, 2010 -- Study Highlights: 25 volunteers from previously conducted Phase 2a trial were "re-vaccinated" with the vaccine after 7 years as part of a Phase 2 trial. Two thirds of the study volunteers responded...

Orphagen Pharmaceuticals Awarded Phase 2 SBIR Funding to Investigate Novel Drug Class for CNS Disorders
San Diego, February 1, 2010-- Orphagen Pharmaceuticals announced today that it has been awarded a twoyear federal grant to further characterize a novel class of small molecule drugs with potential to treat circadian...